IPCALAB:NSE
IPCA Laboratories Ltd
₹1,906.00
arrow_upward
+1.27%(+23.90) 1D
Aug 19, 3:30:00 PM GMT+5:30 · INR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPCALAB...
Open
₹1,882.10
High
₹1,937.90
Low
₹1,863.00
Mkt. cap
483.56B
Avg. vol.
0.00
Volume
753.33K
Dividend
0.31%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
36.92
52-wk high
₹1,945.10
52-wk low
₹1,251.60
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
Open
₹1,882.10
High
₹1,937.90
Low
₹1,863.00
Mkt. cap
483.56B
Avg. vol.
0.00
Volume
753.33K
Dividend
0.31%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
36.92
52-wk high
₹1,945.10
52-wk low
₹1,251.60
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
News stories
From web sources and news partners
TradingView
·
2 days ago
Ipca Laboratories shares gain 5.35% to Rs 1,827
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd
AI content may include mistakes. Learn more